Drug Patents owned by Otter Pharms

1. Drug name - OTREXUP

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9533102 OTTER PHARMS Prefilled syringe jet injector Jan, 2026

(3 years from now)

US9629959 OTTER PHARMS Prefilled syringe jet injector Jan, 2026

(3 years from now)

US8562564 OTTER PHARMS Prefilled syringe jet injector Jan, 2026

(3 years from now)

US8021335 OTTER PHARMS Prefilled syringe jet injector Oct, 2026

(3 years from now)

US9867949 OTTER PHARMS Injector safety device Mar, 2029

(6 years from now)

US10709844 OTTER PHARMS Injector safety device Mar, 2029

(6 years from now)

US9421333 OTTER PHARMS Hazardous agent injection system Mar, 2030

(7 years from now)

US8945063 OTTER PHARMS Hazardous agent injection system Mar, 2030

(7 years from now)

US8579865 OTTER PHARMS Hazardous agent injection system Mar, 2030

(7 years from now)

US8480631 OTTER PHARMS Hazardous agent injection system Mar, 2030

(7 years from now)

US8814834 OTTER PHARMS Injector safety device May, 2031

(8 years from now)

Drugs and Companies using METHOTREXATE ingredient

Treatment: Subcutaneous injection of methotrexate

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
7.5MG/0.4ML (7.5MG/0.4ML) SOLUTION;SUBCUTANEOUS Discontinued
10MG/0.4ML (10MG/0.4ML) SOLUTION;SUBCUTANEOUS Discontinued
12.5MG/0.4ML (12.5MG/0.4ML) SOLUTION;SUBCUTANEOUS Prescription
15MG/0.4ML (15MG/0.4ML) SOLUTION;SUBCUTANEOUS Prescription
17.5MG/0.4ML (17.5MG/0.4ML) SOLUTION;SUBCUTANEOUS Prescription
20MG/0.4ML (20MG/0.4ML) SOLUTION;SUBCUTANEOUS Prescription
22.5MG/0.4ML (22.5MG/0.4ML) SOLUTION;SUBCUTANEOUS Prescription
25MG/0.4ML (25MG/0.4ML) SOLUTION;SUBCUTANEOUS Prescription
15MG/0.6ML (15MG/0.6ML) SOLUTION;SUBCUTANEOUS Discontinued
17.5MG/0.7ML (17.5MG/0.7ML) SOLUTION;SUBCUTANEOUS Discontinued
20MG/0.8ML (20MG/0.8ML) SOLUTION;SUBCUTANEOUS Discontinued
22.5MG/0.9ML (22.5MG/0.9ML) SOLUTION;SUBCUTANEOUS Discontinued
25MG/ML (25MG/ML) SOLUTION;SUBCUTANEOUS Discontinued

availability in other generic markets.

Click on the highlighted region to filter.